These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12186531)

  • 21. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.
    Jafar TH; Stark PC; Schmid CH; Landa M; Maschio G; de Jong PE; de Zeeuw D; Shahinfar S; Toto R; Levey AS;
    Ann Intern Med; 2003 Aug; 139(4):244-52. PubMed ID: 12965979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises.
    Schieppati A; Remuzzi G
    Kidney Int; 2003 Dec; 64(6):1947-55. PubMed ID: 14633117
    [No Abstract]   [Full Text] [Related]  

  • 24. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G
    Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.
    Swislocki AL; Siegel D
    Am J Manag Care; 2001 Mar; 7(3):283-95. PubMed ID: 11258145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Remission Clinic approach to halt the progression of kidney disease.
    ;
    J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Slowing nephropathy progression: focus on proteinuria reduction.
    Bakris GL
    Clin J Am Soc Nephrol; 2008 Jan; 3 Suppl 1(Suppl 1):S3-10. PubMed ID: 18178794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Questions and answers from controlled clinical trials of antihypertensive therapy in progressive renal disease.
    Kasiske BL
    Am J Hypertens; 1992 Oct; 5(10):778-9. PubMed ID: 1418845
    [No Abstract]   [Full Text] [Related]  

  • 29. Angiotensin converting enzyme inhibitors: the end of end-stage renal disease?
    Feig PU; Rutan GH
    Ann Intern Med; 1989 Sep; 111(6):451-3. PubMed ID: 2672924
    [No Abstract]   [Full Text] [Related]  

  • 30. Progressive renal and cardiovascular disease: optimal treatment strategies.
    Weir MR
    Kidney Int; 2002 Oct; 62(4):1482-92. PubMed ID: 12234333
    [No Abstract]   [Full Text] [Related]  

  • 31. [Angiotensin-converting enzyme inhibitors in the diagnosis and treatment of kidney diseases].
    Dzúrik R; Dzúriková V; Stefíková K
    Vnitr Lek; 1991 Jun; 37(6):612-9. PubMed ID: 1897143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

  • 33. ACE inhibitors and AT1 receptor antagonists: is two better than one?
    Noris M; Remuzzi G
    Kidney Int; 2002 Apr; 61(4):1545-7. PubMed ID: 11918763
    [No Abstract]   [Full Text] [Related]  

  • 34. [Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].
    Mayr M; Dickenmann MJ
    Schweiz Med Wochenschr; 2000 Apr; 130(13):491. PubMed ID: 10812646
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical trials of renin-angiotensin antagonists in Japan].
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):182-3. PubMed ID: 18421845
    [No Abstract]   [Full Text] [Related]  

  • 36. Is angiotensin-converting enzyme inhibitor appropriate for contrast-induced nephropathy? A meta-analysis about this field.
    Li X; Li T; Fu N; Hu Y; Cong H
    Int J Cardiol; 2012 Mar; 155(3):486-8. PubMed ID: 22264872
    [No Abstract]   [Full Text] [Related]  

  • 37. Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease.
    de Jong PE; Heeg JE; Apperloo AJ; de Zeeuw D
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):85-8. PubMed ID: 2024682
    [No Abstract]   [Full Text] [Related]  

  • 38. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons?
    Sarafidis PA; Bakris GL
    Ann Intern Med; 2009 May; 150(10):731-3. PubMed ID: 19451583
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
    Nakao N; Yoshimura A; Morita H; Takada M; Kayano T; Ideura T
    Lancet; 2003 Jan; 361(9352):117-24. PubMed ID: 12531578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ACE inhibitors in non-diabetic renal disease.
    Fluck RJ; Raine AE
    Br Heart J; 1994 Sep; 72(3 Suppl):S46-51. PubMed ID: 7946803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.